Navegando por Palavras-chave "tumor markers"
Agora exibindo 1 - 6 de 6
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAnálise do tempo de sobrevida de doentes com adenocarcinoma colorretal esporádico pela utilização de um painel de biomarcadores de carcinogênese constituído por vegf, egfr, ki-67, p53 e bcl-2(Universidade Federal de São Paulo (UNIFESP), 2014-12-17) Luderer, Loreley Andrade [UNIFESP]; Matos, Delcio Matos [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: To evaluate the prognostic power of survival of a carcinogenesis biomarkers panel formed by p53, VEGF, Bcl-2, Ki-67, and EGFR in subjects with sporadic colorectal adenocarcinoma subjected to radical surgical treatment. Methods: 114 post-surgical subjects with colorectal adenocarcinoma were studied and followed for 3 to 5 years at Fundação Pio XII – Hospital de Câncer de Barretos. The study was conducted in paraffin-embedded tumor tissue whose slides were stained using the hematoxylin-eosin technique. The tissue microarray slides, as well as the immunohistochemical staining, were examined by two pathologists, blinded to the evaluations. The statistical analyses were conducted using mean, median, minimum, maximum, and number of valid observations for the descriptive analysis of the numeric variable, global survival. The comparison of the expression of EGFR, VEGF, Ki-67, p53, and Bcl-2 biomarkers was conducted through the Chi-square test or, when required, Fisher’s exact test. The Cox regression model was used for global survival analysis with a panel of markers and for uni and multivariate global survival analyses. Results: Isolated expression correlation results of the markers with the variables: age, differentiation degree, venous invasion, perineural invasion, TNM (I+II) x (III+IV), and survival showed statistically significant differences in the EGFR expression with venous invasion, TNM classification, and global survival; the expression of the VEGF marker has showed significant correlation with the perineural invasion; the Ki-67 marker, with age, venous invasion, and TNM; expression of p53 was significantly related with age, venous invasion, TNM, and global survival; the Bcl-2 marker did not show significant correlation with any of the variables analyzed. The survival analysis, using the markers panel, has significantly showed lesser time of survival in surgical species with 60% or more overexpression. Conclusion: Overexpression of the selected tumor markers panel is related with lesser time of survival in those suffering from sporadic colorectal adenocarcinoma subjected to radical surgical treatment.
- ItemAcesso aberto (Open Access)Cancer causing viruses and the role of laboratory medicine: literature review and perspectives(Sociedade Brasileira de Patologia ClínicaSociedade Brasileira de PatologiaSociedade Brasileira de Citopatologia, 2013-04-01) Passos, Ana Maria [UNIFESP]; Granato, Celso Francisco Hernandes [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Cancer-causing viruses are responsible for up to 20% of cancers with infectious etiology, representing a serious public health problem worldwide. Since the discovery of the first human cancer-causing virus, several others have been associated with neoplasias. Recent advances in technologies for the determination of genomic and proteomic profiles have resulted in the discovery and availability of tumor markers with potential application in the screening, diagnosis, prognosis and treatment of cancer. Therefore, laboratory medicine has stood out as a fundamental tool in the prevention and management of these diseases.
- ItemSomente MetadadadosEarly nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-BETA 1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma(Veda, Slovak Academy Sciences, 2004-01-01) Morena, Ana Maria Lira [UNIFESP]; Oshima, Celina Tizuko Fujiyama [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Egami, Mizue Imoto [UNIFESP]; Silva, Maria Regina Regis da [UNIFESP]; Segreto, Roberto Araujo [UNIFESP]; Giannotti Filho, Osvaldo [UNIFESP]; Teixeira, Vicente de Paulo Castro [UNIFESP]; Segreto, Helena Regina Comodo [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Oncoctr Fdn Sao PauloThe purpose of the present study was to evaluate breast carcinoma samples before and two days after treatment with tamoxifen in order to analyse early histopathological alterations - particularly nuclear alterations - as well as immunohistochemical expression of Ki-67, Erb-B2, VEGF, TGf-beta 1 and ILK proteins. Twenty one cases of invasive ductal and lobular breast carcinoma were studied. Patients were submitted to biopsy of the lesion and, after confirmation of the diagnosis, they received 20 mg of tamoxifen a day, beginning two days before surgery. The samples obtained during biopsy and after surgery were stained with HE for histopathological diagnosis. Estrogen receptor was positive in IS cases and negative in 3. The immunohistochemical method was applied for the detection of Ki-67, Erb-B2, protein, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-beta 1) and integrin linked kinase (ILK).Two days after tamoxifen treatment, the following results were observed: 1) decrease in the cell volume, chomatine condensation, nucleoli less evident and clearly defined nuclear limits; 2) significant reduction in the expression of Erb-B2 protein and significant increase in the expression of TGF-beta 1 protein; 3) expression of others proteins (Ki-67, VEGF and ILK) was not altered during the indicated time frame.Our results suggest that analyzing nuclear alterations and expression of Erb-B2 and TGF-beta 1 proteins would be useful to assess the initial response to tamoxifen.
- ItemSomente MetadadadosHeparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis(Neoplasia Press, 2007-06-01) Theodoro, Therese Rachell; Matos, Leandro Luongo de [UNIFESP]; Sant'Anna, Aleksandra Vanessa Lambiasi; Fonseca, Fernando Luiz Affonso [UNIFESP]; Semedo, Patricia [UNIFESP]; Martins, Lourdes Conceicao; Nader, Helena Bonciani [UNIFESP]; Del Giglio, Auro; Pinhal, Maria Aparecida da Silva [UNIFESP]; Fac Med ABC; Universidade Federal de São Paulo (UNIFESP)Heparanase is an endo-beta-glucuronidase that is capable of degrading heparan sulfate chains of proteoglycans, generating a variety of bioactive molecules such as growth factors and chemotactic and angiogenic agents. the expression of heparanase was investigated in the peripheral blood mononuclear cell fraction ( PBMC) of 30 patients with breast cancer and 20 healthy control women by reverse transcription-polymerase chain reaction ( RT-PCR) and immunocytochemistry. PBMC samples from all breast cancer patients at study entry showed the expression of heparanase, whereas no expression was observed for healthy women. Immunocytochemistry analysis demonstrated that heparanase was expressed in lymphocytes of breast cancer PBMC. Throughout follow-up, heparanase expression by RTPCR decreased significantly after surgery in patients treated with neoadjuvant chemotherapy ( P = .002) and after tamoxifen treatment ( P = .040), whereas it increased significantly with the advent of systemic metastasis ( P = .027). in vitro, either serum from breast cancer patients or a medium originated from co-culture experiments of MCF-7 cells and lymphocytes from healthy women stimulated heparanase expression in normal lymphocytes. the results suggest that there is a tumor-inducing effect on heparanase expression by lymphocytes present in the PBMCs of breast cancer patients, which depends, in turn, on the interaction between a tumor and normal lymphocytes.
- ItemSomente MetadadadosNeuron specific enolase concentration is increased in serum and decreased in platelets of patients with active systemic sclerosis(J Rheumatol Publ Co, 2003-12-01) Massabki, Paulo S.; Silva, Neusa P.; Lourenco, Dayse M.; Andrade, Luis EC; Universidade Federal de São Paulo (UNIFESP)Objective. To determine frequency, origin, and clinical associations of, elevated serum neuron specific enolase (NSE) in systemic sclerosis (SSc).Methods. Serum was obtained from 75 patients with SSc, 20 systemic lupus erythematosus, 8 polymyositis, 10 idiopathic interstitial lung disease, and 10 healthy volunteers. NSE status was determined in serum (in all individuals) and in platelet lysate (in volunteers and 30 patients with SSc).Results. Elevated serum NSE (mean 22.6 ng/ml, range 12.1-68.2 ng/ml) was observed in 26 patients with SSc (34.6%). Those with diffuse SSc had higher serum NSE than those with limited disease (16.5 +/- 13.4 vs 9.6 +/- 5.0 ng/ml, p = 0.006). No association was found between serum NSE and lung or esophagus involvement. Patients with long-standing disease had lower serum NSE than those with early disease (10.8 +/- 7.3 vs 16.1 +/- 13.6 ng/ml, p = 0.05). Serum NSE was 19.4 +/- 13.0 ng/ml in patients with total skin score (TSS) > 20, 8.3 +/- 2.1 ng/ml in patients with TSS < 5, and 6.0 +/- 3.1 ng/ml in volunteers (p = 0.01). NSE platelet lysate concentration was 3.6 +/- 2.9 ng/ml in patients with TSS > 20, 12.4 +/- 4.1 ng/ml in those with TSS < 5, and 14.1 +/- 6.5 ng/ml in healthy individuals (p < 0.001). Volunteers and SSc patients with low TSS had comparable S/PL-NSE index (serum/platelet lysate NSE concentration) (0.42 +/- 0.16 and 0.75 +/- 0.33, respectively), both lower than SSc patients with high TSS (7.45 +/- 5.57) (p < 0.001).Conclusion. Elevated serum NSE was observed in one-third of SSc patients but not in other autoimmune rheumatic diseases. The inverse relationship between serum and platelet lysate NSE concentration suggests platelet activation as the origin of high serum NSE in SSc. NSE S/PL was the best discriminatory variable between healthy volunteers and SSc patients as well as between patients with high and low TSS. High serum NSE and high NSE-S/PL index seemed to be associated with SSc disease activity. Further work is warranted to investigate a possible role for this marker in assessing disease activity and therapy response.
- ItemSomente MetadadadosOverexpression of the ITGAV Gene Is Associated with Progression and Spread of Colorectal Cancer(Int Inst Anticancer Research, 2014-10-01) Waisberg, Jaques [UNIFESP]; Viana, Luciano de Souza [UNIFESP]; Affonso Junior, Renato Jose [UNIFESP]; Silva, Sandra Regina Morini da [UNIFESP]; Denadai, Marcos Vinicius Araujo [UNIFESP]; Margeotto, Fernando Beani; Souza, Carolina Salinas de [UNIFESP]; Matos, Delcio [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Barretos Canc Hosp; ABC Med SchBackground/ Aim: The interaction of neoplastic cells with the extracellular matrix is a critical event for the initiation of cancer invasion and metastasis. We evaluated the relationship between the expression of SPARC, ITGAV, THBS1 and VCAM-1 genes of extracellular matrix in the progression and dissemination of colorectal cancer (CRC). Patients and Methods: Adult patients (N=114) underwent resection of CRC. Gene expression in CRC was determined by quantitative real-time polymerase chain reaction (PCR). Protein expression was analyzed by immunohistochemistry (IHC). Correlation with pathway-related molecules (p53, Bcl-2, Ki-67, EGFR and VEGF) was assessed. Results: Tumors with perineural invasion showed overexpression (p=0.028) of the ITGAV gene with regard to cancers without perineural invasion and validation of the result through IHC expression of the corresponding proteins, was significant for the expression of ITGAV protein (p=0.001). Conclusion: The overexpression of ITGAV gene was associated with higher progression and spread of CRC via perineural invasion.